Skip to Content

Join the 'Polycythemia Vera' group to help and get support from people like you.

Polycythemia Vera News

FDA Approves Jakafi (ruxolitinib) for Polycythemia Vera

Posted 4 Dec 2014 by Drugs.com

December 4, 2014 – The U.S. Food and Drug Administration today approved a new use for Jakafi (ruxolitinib) to treat patients with polycythemia vera, a chronic type of bone marrow disease. Jakafi is the first drug approved by the FDA for this condition. Polycythemia vera occurs when too many red blood cells are made in the bone marrow. Patients may also experience an increase in white blood cells and platelets. An overabundance of blood cells can cause the spleen to swell, bleeding problems and blood clots in the veins near the skin surface (phlebitis). In addition, it puts patients at increased risk of stroke or heart attack. Jakafi’s new use is intended to treat polycythemia vera patients who have an inadequate response to or cannot tolerate hydroxyurea, another medicine often prescribed to reduce the number of red blood cells and platelets in the blood. Jakafi works by inhibiting e ... Read more

Related support groups: Polycythemia Vera, Ruxolitinib, Jakafi

Jakafi Approved for Chronic Bone Marrow Disease

Posted 4 Dec 2014 by Drugs.com

THURSDAY, Dec. 4, 2014 – Jakafi (ruxolitinib) has been approved by the U.S. Food and Drug Administration to treat polycythemia vera, a chronic disease of the bone marrow. Jakafi is the first FDA-sanctioned drug for the disease, which occurs when too many red blood cells are produced in the bone marrow. This may lead to a swollen spleen and phlebitis, characterized by blood clots near the surface of the skin. The disease also increases the risk of heart attack, the agency said Thursday in a news release. Jakafi has been approved for polycythemia vera patients who cannot tolerate or have an inadequate response to other drugs. In clinical studies involving 222 people, Jakafi's most common side effects included low counts of red blood cells and blood platelets, dizziness, constipation and shingles. The drug was first approved in 2011 to treat another bone marrow disorder, myelofibrosis. ... Read more

Related support groups: Polycythemia Vera, Jakafi

Ask a Question

Further Information

Related Condition Support Groups

Polycythemia

Related Drug Support Groups

hydroxyurea, ruxolitinib, Jakafi